Patient Navigation for HER2+ Metastatic Breast Cancer Patients Treated With Tucatinib

NANot yet recruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

January 31, 2026

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions
HER2+ Metastatic Breast Cancer (MBC)
Interventions
BEHAVIORAL

Patient Navigation Program

The patient navigation program will integrate 1) education to enhance understanding of the treatment regimen, follow-up care, and the importance of adherence, 2) symptom management and adherence strategies, and 3) skills and resources to enhance women's symptom coping and self-management abilities.

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Duke University

OTHER